Avonex Pen Injection, Solution
NDC Package 59627-003-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Avonex Pen (interferon beta-1a) injection is a medication used to treat multiple sclerosis (MS). This formulation utilizes a injection, solution delivery system. Marketed by Biogen Inc., this product is identified by NDC 59627-003 and is authorized under FDA application BLA103628.

Identification & Billing

NDC Package Code
59627-003-01
Package Description
1 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE
Product Code
59627-003
11-Digit Billing Format
59627000301
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Avonex Pen
Non-Proprietary Name
Interferon Beta-1a
Substance Name
Interferon Beta-1a
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
INTERFERON BETA-1A 30 ug/.5mL
Pharmacologic Class
Usage Information
This medication is used to treat multiple sclerosis (MS). Interferon is not a cure for MS, but it may help to slow disease worsening and decrease flare-ups of symptoms (such as balance problems, numbness, or weakness).

Regulatory & Marketing

Labeler Name
Biogen Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA103628
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
05-23-2003
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 59627-003-01 identifies a specific commercial package of 1 syringe in 1 carton / .5 ml in 1 syringe of Avonex Pen, a human prescription drug labeled by Biogen Inc.. This injection, solution is formulated for intramuscular use and contains interferon beta-1a as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Biogen Inc. on May 23, 2003. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat multiple sclerosis (MS). Interferon is not a cure for MS, but it may help to slow disease worsening and decrease flare-ups of symptoms (such as balance problems, numbness, or weakness).

How is this Biogen Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 59627000301. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
59627-003-01
11-Digit CMS (5-4-2)
59627-0003-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.